Peikert Alexander, Vaduganathan Muthiah, Claggett Brian L, Kulac Ian J, Litwin Sheldon, Zile Michael, Desai Akshay S, Jhund Pardeep S, Butt Jawad H, Lam Carolyn S P, Martinez Felipe, Van Veldhuisen Dirk J, Zannad Faiez, Rouleau Jean, Lefkowitz Martin, McMurray John J V, Solomon Scott D, Packer Milton
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
University Heart Center Graz, Department of Cardiology, Medical University of Graz, Graz, Austria.
Eur Heart J. 2025 Jan 28. doi: 10.1093/eurheartj/ehaf057.
An expansion of fat mass is an integral feature of patients with heart failure and preserved ejection fraction (HFpEF). While body mass index (BMI) is the most common anthropometric measure, a measure of central adiposity-the waist-to-height ratio (WHtR)-focuses on body fat content and distribution; is not distorted by bone or muscle mass, sex, or ethnicity; and may be particularly relevant in HFpEF.
The PARAGON-HF trial randomized 4796 patients with heart failure and ejection fraction ≥45% to valsartan or sacubitril/valsartan. The current work characterizes the association of BMI and WHtR with clinical features, outcomes, and the response to neprilysin inhibition.
About half (49%) of the participants were considered obese by BMI (≥30 kg/m2), but nearly every patient (96%) had central adiposity (WHtR ≥0.5). Among patients who were not obese (BMI <30 kg/m2), 860 (37%) had marked central adiposity (WHtR ≥0.6). Higher BMI and WHtR were both associated with higher risk of total heart failure hospitalizations, but as compared with BMI, WHtR was linearly associated with heart failure outcomes and identified a higher proportion of patients who had a particularly elevated risk (i.e., 30% or greater). An obesity-survival paradox (i.e., improved outcomes in those with greater adiposity) was apparent with BMI in unadjusted analyses, but it was not observed with WHtR. Although neprilysin inhibition appeared to have greater effects on heart failure outcomes in patients with higher BMI and WHtR, analyses of interaction with obesity metrics did not show significant heterogeneity across the range of values for adiposity.
In PARAGON-HF, in contrast with BMI, nearly every patient with HFpEF had central adiposity (as assessed by WHtR), and the risks of adverse heart failure events were more robustly related to WHtR. These data challenge the current reliance on BMI as an appropriate metric of adiposity, and they suggest that-rather than obesity-related HFpEF being regarded as a select HFpEF subgroup-central adiposity is a ubiquitous feature of HFpEF.
脂肪量增加是射血分数保留的心力衰竭(HFpEF)患者的一个重要特征。虽然体重指数(BMI)是最常用的人体测量指标,但中心性肥胖的一个指标——腰高比(WHtR)——关注的是身体脂肪含量和分布;不受骨骼或肌肉量、性别或种族的影响;并且在HFpEF中可能特别相关。
PARAGON-HF试验将4796例射血分数≥45%的心力衰竭患者随机分为缬沙坦组或沙库巴曲/缬沙坦组。目前的研究描述了BMI和WHtR与临床特征、结局以及对中性肽链内切酶抑制反应之间的关联。
约一半(49%)的参与者根据BMI被认为肥胖(≥30kg/m²),但几乎每位患者(96%)都有中心性肥胖(WHtR≥- 0.5)。在非肥胖患者(BMI<30kg/m²)中,860例(37%)有明显的中心性肥胖(WHtR≥0.6)。较高的BMI和WHtR均与心力衰竭住院总风险较高相关,但与BMI相比,WHtR与心力衰竭结局呈线性相关,且识别出更高比例的风险特别升高的患者(即30%或更高)。在未经调整的分析中,BMI存在肥胖-生存悖论(即肥胖程度较高者结局改善),但WHtR未观察到这一现象。虽然中性肽链内切酶抑制似乎对BMI和WHtR较高的患者的心力衰竭结局有更大影响,但与肥胖指标的相互作用分析未显示在肥胖值范围内存在显著异质性。
在PARAGON-HF研究中,与BMI不同,几乎每位HFpEF患者都有中心性肥胖(通过WHtR评估),心力衰竭不良事件风险与WHtR的相关性更强。这些数据挑战了目前将BMI作为肥胖合适指标的做法,并表明——与其将肥胖相关的HFpEF视为特定的HFpEF亚组——中心性肥胖是HFpEF的普遍特征。